Company intelligence / Profile preview
TrAMPoline Pharma
Aurora, Colorado, United Statestrampolinepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TrAMPoline Pharma is developing next-generation gene-modified tumor infiltrating lymphocyte therapies. Their lead product MightyTIL™ (TP‑102) has demonstrated superior efficacy in vitro and in vivo compared to conventional unmodified TILs. The company has secured over $15M in funding to support a first-in-human clinical trial expected to begin in early 2026. Additional pipeline programs aim to further enhance TIL function, increase yield/quality prior to harvest, and develop a universal TCR-T cell candidate.
- Therapeutic areas
- Oncology
- Modalities
- Gene-modified cell therapyTumor-infiltrating lymphocyte (TIL) therapyCellular immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gates Biomanufacturing Facility at University of Colorado Anschutz Medical Campus [manufacturing partnership]
Beyond the preview
Go deeper on TrAMPoline Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TrAMPoline Pharma.